J B Hunt Transport Services Inc vs Johnson & Johnson — how do they compare? J B Hunt Transport Services Inc trades at $292.15 (market cap $27.36B), while Johnson & Johnson trades at $249.4 (market cap $598.96B). The key difference: Johnson & Johnson is far larger — about 21.9× J B Hunt Transport Services Inc's market cap, and Johnson & Johnson pays the higher dividend (2.15%). Which is the better fit depends on your goals.
| JBHT | JNJ | |
|---|---|---|
Market Cap | $27.36B | $598.96B |
Sector | Industrials | Health |
52-Week High | $298.41 | $267.24 |
52-Week Low | $130.65 | $164.36 |
Enterprise Value | $28.50B | $631.90B |
Dividend Yield | 0.62% | 2.15% |
Volume | — | 6,156,228 |
Signals from Pluang's Aura AI — not financial advice
JBHT trades at $290.43, down 0.34% today but near its 52-week high, with a bullish technical outlook and consistent earnings beats. The stock shows strong momentum, supported by intermodal growth and cost discipline. Recent Q2 2026 EPS of $1.91 beat estimates by 12%, driving positive sentiment. Valuation remains elevated with a P/E of 41.45, reflecting high growth expectations amid industry capacity constraints.
Outlook is positive due to structural freight market shifts and operational efficiency, but risks include premium valuation sensitivity and economic cyclicality. Analyst consensus favors Buy with a $299.82 target, suggesting modest upside. Investors should weigh robust fundamentals against potential margin pressures from rising costs.
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
Trailing returns across standard periods
Latest headlines on both assets
J.B. Hunt Transport Services ranks among the top surface transportation companies in North America by revenue. Its primary operating segments are intermodal delivery, which uses the Class I rail carriers for the underlying line-haul movement of its owned containers (45% of sales in 2021).
Read more on JBHT →Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →